4 / 20
allied
academies
Biochem Mol biol J
ISSN: 2471-8084
Volume 3, Issue 2
Metabolomics Conference 2017
August 29-30, 2017 Prague, Czech Republic
9
th
International Conference and Exhibition on
Metabolomics and Systems Biology
Notes:
Page 18
Blood-based metabolomic biomarkers for
human neurological disorders
Massimo S Fiandaca
1
, Mark Mapstone
1
, Amin Mahmoodi
1
, Thomas
Gross
1
, Amrita K Cheema
2
, Fabio Macciardi
1
, Kian Merchant-Borna
3
,
Jeff Bazarian
3
and
Howard J Federoff
1
1
University of California, Irvine, USA
2
Georgetown University, USA
3
University of Rochester Medical Center, USA
F
ormanyhumanmaladies, especiallyneurodegenerative
disorders (e.g., Alzheimer’s disease, AD, and
Parkinson’s disease, PD) the ability to predict disease risk
during asymptomatic stages is essential for earlier and
more efficacious interventions. Blood-based biomarkers
for AD (and PD), once defined and validated, may facilitate
the participation of at-risk asymptomatic individuals
in therapeutic clinical trials, and thereby increase the
potential for successful prevention and/or disease
modification. In conditions such as mild traumatic brain
injury (mTBI), relevant blood bio-signatures could provide
unbiased diagnostics that significantly improve clinical
decision-making and improved treatments. Blood-based
metabolomic biomarkers may offer such diagnostic and
therapeutic potential in both AD and mTBI, as evidenced
by our recent work. In this seminar, I plan to discuss
our group’s approaches to blood-based metabolomic
biomarker development and present results from our
most recent metabolomic investigations related to AD
and mTBI. We are encouraged by the potential provided
by both untargeted and targeted metabolomic platforms
in defining annotated species that are germane to the
respective clinical conditions. We also provide caution to
those exploring this area of research since there are many
confounding factors that need close scrutiny in an effort to
maximize clinical utility.
Biography
Massimo S Fiandaca is a Neuroscientist and Associate Professor in the
Department of Neurology and Neurological Surgery at University of California
Irvine (UCI). As Co-director of the Federoff Translational Laboratory and
Biorepository (TLaB) at UCI, he is currently focused on blood-based
biomarkers related to neurological disorders. Through established local,
national, and international collaborations, he and his colleagues hope to impact
the development of relevant blood-based biomarkers for a variety of conditions
affecting the nervous system. He is a board certified Neurological Surgeon,
who retired from surgical practice after 25 years, and returned to full-time
academic research and teaching. His past research experiences have focused
on direct brain delivery of therapeutics for neurodegenerative disorders and
neuro-oncology, including cellular and tissue transplantation, viral-vector
based therapeutic gene delivery, MRI-directed convection-enhanced delivery,
and nano-liposomal therapeutics.
mfiandac@uci.eduMassimo S Fiandaca et al., Biochem Mol biol J, 3:2
DOI: 10.21767/2471-8084-C1-002